Toronto Dominion Bank bought a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 891,366 shares of the company's stock, valued at approximately $3,655,000. Toronto Dominion Bank owned about 5.05% of Exagen at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of the stock. Northern Trust Corp lifted its holdings in shares of Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after acquiring an additional 2,630 shares during the last quarter. Palumbo Wealth Management LLC raised its holdings in Exagen by 13.5% in the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock worth $355,000 after purchasing an additional 10,340 shares in the last quarter. Geode Capital Management LLC raised its holdings in Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock worth $402,000 after purchasing an additional 10,442 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Exagen in the 4th quarter worth about $45,000. Finally, Virtu Financial LLC purchased a new stake in shares of Exagen in the 4th quarter worth about $46,000. 75.25% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have recently weighed in on XGN. Cantor Fitzgerald reduced their target price on shares of Exagen from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. BTIG Research reiterated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Canaccord Genuity Group raised their price objective on shares of Exagen from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Tuesday, May 13th. UBS Group reissued an "overweight" rating on shares of Exagen in a report on Thursday, May 15th. Finally, William Blair reaffirmed an "outperform" rating on shares of Exagen in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $7.50.
View Our Latest Report on XGN
Exagen Trading Up 4.5%
Exagen stock opened at $6.03 on Friday. The stock has a market cap of $128.44 million, a P/E ratio of -6.41 and a beta of 1.50. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen Inc. has a 1 year low of $1.71 and a 1 year high of $7.20. The firm's 50 day moving average price is $5.01 and its 200-day moving average price is $4.31.
Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The company had revenue of $15.50 million for the quarter, compared to analysts' expectations of $14.55 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. On average, equities analysts predict that Exagen Inc. will post -0.88 earnings per share for the current fiscal year.
About Exagen
(
Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Further Reading
Want to see what other hedge funds are holding XGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exagen Inc. (NASDAQ:XGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
